Showing papers by "Dagfinn Albrechtsen published in 1987"

Depletion of T lymphocytes from human bone marrow: use of magnetic monosized polymer microspheres coated with T-lymphocyte-specific monoclonal antibodies

Abstract: A new technique for depletion of T cells from bone marrow is presented. Bone marrow cells (BMC) were rosetted with magnetic monosized polystyrene microspheres coated with monoclonal antibodies (MAbs) specific for T cell CD2 and CD3 antigens. Rosetted T cells were subsequently removed from non-T cells with the aid of a magnet. This immunomagnetic separation procedure was carried out in less than 40 min and reproducibly removed T cells, leaving a maximum of 0.025% sheep-red-blood-cell (SRBC) rosette-forming cells and less than 0.02% T cells as detected by a T cell limiting dilution assay. The efficacy of the depletion procedure was further shown by flow cytometry data, by effective removal of cells from a T cell line added to the BMC prior to immunomagnetic separation, and by abrogation of interleukin 2 (IL-2)-producing capacity in T-cell-depleted BMC (BMC-T). The T cell depletion procedure provided a 43-74% recovery of non-T cells present in the Isopaque-Ficoll-isolated bone marrow mononuclear cell fraction and did not disturb the growth potential of stem cells, as assayed by hematopoietic stem cell assays.

No difference in outcome between 314 nontransfused and 614 transfused cadaveric renal transplant recipients: the Scandinavian experience.

Abstract: Pretransplant blood transfusions had no beneficial effect on the graft survival rate, the rejection frequency, or the quality of graft function in a case material consisting of 928 cadaveric kidney transplant recipients treated with 3 different CsA dose protocols. When younger recipients, PRA-negative recipients, or recipients receiving poorly HLA-matched kidneys were analyzed separately, there was still no transfusion effect. In the most recent series, the one-year graft survival rate was 84% among 164 nontransfused patients, and in 73 nontransfused patients under 50 years of age it was 90%. We conclude that with present day immunosuppressive therapy, based on CsA, there is no case for pretreatment blood transfusions. Indeed, this practice might place the renal transplant patient at a disadvantage.